Ocuphire Pharma Investor Presentation Deck

Corporate Highlights Late-Stage Retinal Pipeline Represents Multi-Billion Dollar Opportunity in Unmet NPDR Patients APX3330 - Novel, Non-Invasive, Safe Oral Tablet to Treat Diabetic Retinopathy APX Pipeline Driven by a Paradigm Changing, Dual Target Ref-1 Platform for Retinal Diseases Global License Agreement with Viatris to Fund Development and Commercialization of Nyxol for All Refractive Indications co Strong Financial Position to Fund Operations into 2025 Ocuphire PHARMA 35

View entire presentation